From the Department of Thoracic and Cardiovascular Surgery, Korea University Anam Hospital, Seoul, Republic of Korea.
Department of Biostatistics, Korea University College of Medicine, Seoul, Republic of Korea.
Anesth Analg. 2023 Jul 1;137(1):153-161. doi: 10.1213/ANE.0000000000006245. Epub 2022 Nov 1.
We examined the relationship between blood transfusion and long-term adverse events to evaluate the clinical impact of red blood cell (RBC) transfusion on patients undergoing cardiac valve surgery.
From the National Health Insurance Service database, individuals undergoing heart valve surgery were verified, including aortic valve (AV), mitral valve (MV), tricuspid valve (TV), and complex valves (more than 2 valve surgeries). The interested outcomes were incidence of death, ischemic stroke, hemorrhagic stroke, and admission for myocardial infarction during follow-up. Associations between perioperative RBC transfusion and long-term cardiovascular events were analyzed with Cox-proportional hazard model.
Perioperative RBC transfusion (±2 days from the day of surgery) was categorized into 0, 1, 2, and >3 units based on the number of packs transfused. From 2003 to 2019, the data of 58,299 individuals were retrieved (51.6% were male and 58% were aged above 60 years). The median follow-up duration was 5.53 years. Of the total cohort, 86.5% received at least 1 transfusion. In multivariable analysis, adverse cardiovascular event risk proportionally increased with transfusion in a dose-dependent manner. The adjusted hazard ratios and 95% confidence intervals of outcomes after the transfusion of 1, 2, and ≥3 units compared to those with no transfusion were as follows: death, 1.53 (1.41-1.66), 1.97 (1.81-2.14), and 3.03 (2.79-3.29); ischemic stroke, 1.27 (1.16-1.39), 1.31 (1.19-1.44), and 1.51 (1.38-1.66); hemorrhagic stroke, 1.38 (1.16-1.66), 1.71 (1.43-2.05), and 2.31 (1.94-2.76); and myocardial infarction 1.35 (1.13-1.62), 1.60 (1.33-1.91), and 1.99 (1.66-2.38), respectively (all P < .01).
In the analysis of the national cohort, perioperative RBC transfusion during heart valve surgery was associated with adverse cardiovascular outcomes correlated with the volume of RBC transfusion.
本研究旨在探讨输血与长期不良事件之间的关系,以评估心脏瓣膜手术患者接受红细胞(RBC)输血的临床影响。
从国家健康保险服务数据库中,我们筛选出接受心脏瓣膜手术的患者,包括主动脉瓣(AV)、二尖瓣(MV)、三尖瓣(TV)和复合瓣膜(≥2 个瓣膜手术)手术。感兴趣的结局包括随访期间的死亡率、缺血性卒中和出血性卒中和因心肌梗死入院。采用 Cox 比例风险模型分析围手术期 RBC 输血与长期心血管事件之间的关系。
根据输血袋数,将围手术期 RBC 输血(手术前后 2 天内)分为 0、1、2 和 >3 个单位。2003 年至 2019 年,共检索到 58299 名患者的数据(51.6%为男性,58%年龄大于 60 岁)。中位随访时间为 5.53 年。总队列中,86.5%的患者至少接受了 1 次输血。多变量分析显示,输血的不良心血管事件风险呈剂量依赖性增加。与未输血相比,输血 1、2 和≥3 个单位后结局的调整后风险比和 95%置信区间分别为:死亡,1.53(1.41-1.66),1.97(1.81-2.14)和 3.03(2.79-3.29);缺血性卒中,1.27(1.16-1.39),1.31(1.19-1.44)和 1.51(1.38-1.66);出血性卒中,1.38(1.16-1.66),1.71(1.43-2.05)和 2.31(1.94-2.76);心肌梗死 1.35(1.13-1.62),1.60(1.33-1.91)和 1.99(1.66-2.38)(均 P <.01)。
在全国队列分析中,心脏瓣膜手术期间的围手术期 RBC 输血与输血量相关的不良心血管结局相关。